Susan Hall, Global Head of R&D at Valeant Pharmaceuticals International, Inc. (VRX), sold 16,120 shares at $54.50 ($879K) on 2012-03-07, disclosed to the SEC on 2012-03-08.
Open-market sale of $879k VRX by Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.